Dysfunctional Mitochondria Drive Aging Inflammation Through Epigenetic Control

The body accumulates cells that have stopped dividing but refuse to die quietly. Called senescent cells, or colloquially "zombie cells," they linger in tissues and pump out inflammatory molecules—the kind that corrode health over decades. As people age, these cells accumulate, and their chemical output has been linked to frailty, heart disease, cancer, and the neurological decline that marks the end of life. For years, researchers have tried to solve the problem by eliminating the cells entirely. A team at Mayo Clinic and Sanford Burnham Prebys Medical Discovery Institute took a different path: instead of killing the cells, they asked whether the inflammation they produce could simply be switched off.

The answer, published in Nature in July 2026, reveals a mechanism that had been invisible until now. Senescent cells are metabolically active in a specific way—their mitochondria, the structures that generate cellular energy, are damaged and dysfunctional. Earlier work from João Passos's laboratory at Mayo Clinic had shown that these broken mitochondria leak their own DNA and RNA into the cell, triggering immune pathways that sound an inflammatory alarm. But the new research shows that leakage alone is not enough to fully activate the inflammatory response. Something else has to happen.

That something else is a second signal, one that comes from the mitochondria's own metabolism. Senescent cells produce elevated levels of acetyl-CoA, a molecule generated through normal mitochondrial energy production. This acetyl-CoA does not directly cause inflammation. Instead, it enables epigenetic modifications—chemical changes that sit atop the DNA like switches, turning genes on or off without altering the genetic code itself. Helene Martini, the study's first author, explained the two-part process: the leaked mitochondrial DNA and RNA trigger the initial inflammatory signal, but the acetyl-CoA from mitochondrial metabolism provides the molecular permission slip that allows inflammatory genes to become fully active. Without that metabolic signal, the genes remain relatively quiet even when the immune alarm is sounding.

This discovery opened a therapeutic door. The researchers identified SLC25A1, a protein that transports citrate across the mitochondrial membrane and is essential for supplying the acetyl-CoA needed for these epigenetic switches. When they blocked SLC25A1 in their experiments, the available acetyl-CoA dropped, inflammatory genes stayed dampened, and the inflammatory response was reduced—even though the original immune signals from the leaked mitochondrial DNA were still present. The cells themselves were not destroyed. They remained in the tissue, but their capacity to drive chronic inflammation was curtailed.

The finding reframes the aging problem. For decades, the field has pursued senolytic drugs—compounds designed to kill senescent cells outright. The Mayo Clinic work suggests an alternative: leave the cells alone, but interrupt the metabolic machinery that allows them to broadcast inflammation. Passos noted that the strategy represents a shift in thinking. Rather than asking how to eliminate the problem, the team asked how to neutralize its harm. The implications are substantial. If blocking SLC25A1 or similar pathways can reduce the inflammatory load that senescent cells impose on aging tissues, it might be possible to slow or prevent the cascade of diseases—cardiovascular, neurological, metabolic—that accumulate in later life. The work does not yet translate to a drug or a clinical trial, but it identifies a previously unrecognized control point in the inflammatory process, a place where intervention might promote healthier aging without requiring the wholesale destruction of the cells themselves.